Sulfacetamide Sodium Ophthalmic Solution USP, 10% (Sterile)

Manufacturer
Central Texas Community Health Centers
Effective date
2016-01-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:21:54

Label at a glance#

ProductSulfacetamide Sodium
Active ingredientSULFACETAMIDE SODIUM
Label structure11 sections

Indications and uses

For the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against...

Dosage and administration

For conjunctivitis and other superficial ocular infections: Instill one or two drops into the conjunctival sac(s) of the affected eye(s) every two to three hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is seven to ten days. For Trachoma: Instill two drops into the conjunctival sac(s) of the affected eye(s) every two ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

FOR USE IN THE EYES ONLY

DESCRIPTION:

DESCRIPTION SECTION

Sulfacetamide Sodium Ophthalmic Solution USP, 10%, is a sterile, topical, anti-bacterial agent for ophthalmic use. The active ingredient is represented by the following structural formula:

Sulfacetamide Sodium (structural formula)
Sulfacetamide Sodium (structural formula)

C8H9N2NaO3S • H2O

Mol. Wt. 254.24

Chemical name: N-Sulfanilylacetamide monosodium salt monohydrate.

Each mL Contains: ACTIVE: Sulfacetamide Sodium, 100 mg (10%); INACTIVES: Methylcellulose, Sodium Thiosulfate, Purified Water. Sodium Phosphate Monobasic may be added to adjust pH (6.8 - 8.0).

PRESERVATIVES ADDED: Methylparaben 0.05% and Propylparaben 0.01%. The osmolality range is 700-1300 mOsm/kg.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Microbiology:

SPL UNCLASSIFIED SECTION

The sulfonamides are bacteriostatic agents and the spectrum of activity is similar for all. Sulfonamides inhibit bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with aminobenzoic acid through competitive inhibition of the enzyme dihydropteroate synthetase. Resistant strains have altered dihydropteroate synthetase with reduced affinity for sulfonamides or produce increased quantities of aminobenzoic acid.

Topically applied sulfonamides are considered active against susceptible strains of the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species.

Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

For the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma:

Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species.

Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Hypersensitivity to sulfonamides or to any ingredient of the preparation.

WARNINGS:

WARNINGS SECTION

FOR TOPICAL EYE USE ONLY - NOT FOR INJECTION.

FATALITIES HAVE OCCURRED, ALTHOUGH RARELY, DUE TO SEVERE REACTIONS TO SULFONAMIDES INCLUDING STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, FULMINANT HEPATIC NECROSIS, AGRANULOCYTOSIS, APLASTIC ANEMIA AND OTHER BLOOD DYSCRASIAS. Sensitizations may recur when a sulfonamide is readministered, irrespective of the route of administration. Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity. At the first sign of hypersensitivity, skin rash or other serious reaction, discontinue use of this preparation.

PRECAUTIONS:

PRECAUTIONS SECTION

General:

GENERAL PRECAUTIONS SECTION

Prolonged use of topical anti-bacterial agents may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to sulfonamides may also develop.

The effectiveness of sulfonamides may be reduced by the para-aminobenzoic acid present in purulent exudates.

Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration, and crosssensitivity between different sulfonamides may occur.

At the first sign of hypersensitivity, increase in purulent discharge, or aggravation of inflammation or pain, the patient should discontinue use of the medication and consult a physician (see WARNINGS).

Information for patients:

INFORMATION FOR PATIENTS SECTION

To avoid contamination, do not touch tip of container to eye, eyelid or any surface.

Drug Interactions:

DRUG INTERACTIONS SECTION

Sulfacetamide preparations are incompatible with silver preparations.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No studies have been conducted in animals or in humans to evaluate the possibility of these effects with ocularly administered sulfacetamide. Rats appear to be especially susceptible to the goitrogenic effects of sulfonamides, and long-term oral administration of sulfonamides has resulted in thyroid malignancies in these animals.

Pregnancy:

PREGNANCY SECTION

Pregnancy Category C.

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with sulfonamide ophthalmic preparations. Kernicterus may occur in the newborn as a result of treatment of a pregnant woman at term with orally administered sulfonamides. There are no adequate and well-controlled studies of sulfonamide ophthalmic preparations in pregnant women and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman. This product should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

NURSING MOTHERS SECTION

Systemically administered sulfonamides are capable of producing kernicterus in infants of lactating women. Because of the potential for the development of kernicterus in neonates, a decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Pediatric Use:

PEDIATRIC USE SECTION

Safety and effectiveness in children below the age of two months have not been established.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

Bacterial and fungal corneal ulcers have developed during treatment with sulfonamide ophthalmic preparations.

The most frequently reported reactions are local irritation, stinging and burning. Less commonly reported reactions include non-specific conjunctivitis, conjunctival hyperemia, secondary infections and allergic reactions.

Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias (see WARNINGS).

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

For conjunctivitis and other superficial ocular infections:

Instill one or two drops into the conjunctival sac(s) of the affected eye(s) every two to three hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is seven to ten days.

For Trachoma:

Instill two drops into the conjunctival sac(s) of the affected eye(s) every two hours. Topical administration must be accompanied by systemic administration.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Sulfacetamide Sodium Ophthalmic Solution USP, 10%, is supplied in a plastic squeeze bottle with a controlled drop tip in the following size:

15 mL bottle - Prod. No. 03011

DO NOT USE IF IMPRINTED "Protective Seal" WITH YELLOW symbolsymbol IS NOT INTACT

Storage:

STORAGE AND HANDLING SECTION

Store between 2° - 30°C (36° - 86°F).

Sulfonamide solutions, on long standing, will darken in color and should be discarded.

KEEP OUT OF REACH OF CHILDREN.

Revised November 2007

Bausch & Lomb Incorporated
Tampa, FL 33637

©Bausch & Lomb Incorporated

9113200 (Folded)
9113300 (Flat)

PRINCIPAL DISPLAY PANEL - 15 ML Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

CommUnity Care Federally Qualified Centers

SULF.
SOD.
OPHT.SOL
10% 15 ML

Date:

Name:
Dr.

INSTILL 2 DROPS IN AFFECTED EYE(S) 3 TIMES A DAY FOR 7
DAYS.

123456

1/1/01

SULFACETamide SOD10% OPH SOL15MLNDC 76413-126-15

Batch: 123456
Lot: 123456
Exp: 1/1/01
Bausch & Lomb

Federal law prohibits the transfer of this drug to any other person than the patient for whom prescribed.

PRINCIPAL DISPLAY PANEL - 15 ML Bottle Label
PRINCIPAL DISPLAY PANEL - 15 ML Bottle Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1006120sulfacetamide sodium 10 % Ophthalmic SolutionPSN1
1006120sulfacetamide sodium 100 MG/ML Ophthalmic SolutionSCD1
1006120sulfacetamide sodium 10 % Eye DropsSY1
1006120sulfacetamide sodium 10 % Ophthalmic SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SULFACETAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828
0304b7d2-7a07-d53b-750f-36012ae6612eProduct name120140508
64c0cc7e-6478-3ca1-8cd7-9a1251d5a3f6Product name120140508
9ae74339-0a3d-82e9-5dd1-88bd2607bd6bProduct name120140508
e44e38a9-2d9e-b0e2-cce9-490554639f3dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
76413-126-152020-01-31C16284748780-19d75b9d0-54b5-f424-e053-dadaa90a57ceSulfacetamide Sodium Ophthalmic Solution USP, 10% (Sterile)

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
76413-126-15Sulfacetamide Sodium15 mL in 1 BOTTLE, DROPPERSOLUTION/ DROPS151
76413-126-15Sulfacetamide Sodium1 in 1 CARTONSOLUTION/ DROPS11

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
76413-126SULFACETAMIDE SODIUM SOLUTION/ DROPS [CENTRAL TEXAS COMMUNITY HEALTH CENTERS]1Legacy NDC, 2 package rows20160130_171deefc-eaaa-44cd-b651-b5d0cfabe38b.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
24208-670-04ML - Milliliter24208-670484fb3a3-280d-465e-a626-be880f877f1c12012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
76413-12676413-126-15
24208-670

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040066-001SULFACETAMIDE SODIUMSULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-28

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A040066-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-2884e616aacf4f…
2026-08-18 06:07:402026-07A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICATRS1994-12-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-2887673890dc5c…
2021-03-12 10:30 UTC2021-03A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-283f01610625f2…
2019-09-15 20:21 UTC2019-09A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28b00525d2431f…
2019-07-19 19:46 UTC2019-07A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-283f0d92c62455…
2023-05-13 08:27 UTC2023-05A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28053a50430f4f…
2023-01-26 05:58 UTC2023-01A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-283a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040066-001SULFACETAMIDE SODIUM10%SOLUTION/DROPS / OPHTHALMICAT1994-12-28f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A040066-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A040066-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040066-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040066-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040066-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040066-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040066-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040066-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040066-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040066-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040066-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040066-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040066-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040066-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040066-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040066-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040066-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040066-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040066-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040066-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040066-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040066-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040066-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A040066-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040066-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040066-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040066-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A040066-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A040066-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040066-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040066-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040066-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040066-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040066-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040066-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040066-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A040066-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A040066-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A040066-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A040066-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sulfacetamide SodiumSULFACETAMIDE SODIUMBausch & Lomb Incorporated6c1b2658-e756-4f31-9bc8-f99a0baa46372023-08-31Warnings, Adverse reactionsExact identifier
ndc (product): 24208-670
c7226bf4-78b4-42b8-ab15-8ed0eb5da88a171deefc-eaaa-44cd-b651-b5d0cfabe38b2016-01-21Warnings, Adverse reactionsExact identifier
spl id: c7226bf4-78b4-42b8-ab15-8ed0eb5da88a
spl set id: 171deefc-eaaa-44cd-b651-b5d0cfabe38b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.